Combined Treatment for Advanced Gastric Cancer Spread to Liver
Part of Cancer, Digestive system clinical trials.
This study tests a combination of procedures and medications—including a special liver procedure (TACE), heat treatment, and three types of drugs—for gastric cancer that has spread to the liver. It's designed for patients whose cancer has high levels of a protein called HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with gastric cancer confirmed by biopsy that has spread to the liver
- Cancer cells must show high HER2 protein levels (confirmed by lab test)
- Age 18–75 with good overall health (ECOG score 0–1) and expected to live at least 3 months
- At least one liver tumor suitable for TACE or heat treatment, plus one other measurable tumor to track treatment response
- No prior treatment with antibody-drug conjugates (ADC) or certain immunotherapy drugs (anti-PD-1, anti-PD-L1, or CTLA-4 inhibitors)
- Normal or near-normal blood counts, liver function, kidney function, heart function, and blood clotting ability
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
This trial tests a combination treatment for liver cancer that cannot be surgically removed. It combines a procedure called TACE (which blocks blood flow to the tumor) with targeted drugs and immunotherapy (helping your immune system fight the cancer). The goal is to see if this combined approach works better and is safe.
This study looks at whether combining a liver-directed procedure called TACE with tiragolumab and targeted therapy works better for people with unresectable liver cancer that has not spread too far. Researchers will use blood and tissue tests to see how well the treatment works.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
Hear when a new Gastric Cancer With Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.